Advertisement
Canada markets close in 2 hours 36 minutes

  • S&P/TSX

    21,838.03
    -35.69 (-0.16%)
     

  • S&P 500

    5,026.56
    -45.07 (-0.89%)
     

  • DOW

    37,979.35
    -481.57 (-1.25%)
     

  • CAD/USD

    0.7311
    +0.0013 (+0.18%)
     

  • CRUDE OIL

    82.54
    -0.27 (-0.33%)
     

  • Bitcoin CAD

    88,213.05
    -500.59 (-0.56%)
     

  • CMC Crypto 200

    1,396.35
    +13.78 (+1.00%)
     

  • GOLD FUTURES

    2,339.70
    +1.30 (+0.06%)
     

  • RUSSELL 2000

    1,975.14
    -20.29 (-1.02%)
     

  • 10-Yr Bond

    4.7000
    +0.0480 (+1.03%)
     

  • NASDAQ

    15,522.32
    -190.42 (-1.21%)
     

  • VOLATILITY

    16.35
    +0.38 (+2.38%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, DOWNBEAT GDP

Caterpillar sinks 7% after earnings, management sees weakness in Europe, Asia-Pacific

CORRECTED-US FDA panel backs AstraZeneca's prostate cancer drug (April 28)

Reuters
Updated ·1 min read

(In April 28 story, corrects company name in paragraph 1. The story was previously corrected to fix a typo in the headline.)

April 28 (Reuters) - A panel of U.S. Food and Drug Administration advisers on Friday voted for the expanded use of British drugmaker AstraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.

The FDA panel voted 11-1 with one abstention, in favor of using the drug, Lynparza, in combination with other medications – abiraterone and prednisone or prednisolone – to treat a type of treatment-resistant prostate cancer in adult patients. (Reporting by Mariam Sunny, Khushi Mandowara and Aditya Samal in Bengaluru; Editing by Shailesh Kuber)